About 1 in 8 Oral Cancer Drug Prescriptions Never Reach the Patient. Why? About 1 in 8 Oral Cancer Drug Prescriptions Never Reach the Patient. Why?
Although most patients do receive their oral cancer drugs, researchers wanted to understand why some patients don ' t.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - October 20, 2022 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
Johnson & Johnson Reports Q3 2022 Results
New Brunswick, N.J. (October 18, 2022) – Johnson & Johnson (NYSE: JNJ) today announced results for third-quarter 2022. “Our third quarter performance demonstrates our continued strength and resilience across all three of our businesses,” said Joaquin Duato, Chief Executive Officer. “Through the ongoing efforts of our teams around the world, we continue to navigate the dynamic macroeconomic environment and remain focused on delivering transformative healthcare solutions. Looking ahead, I remain confident in our business and ability to continue advancing our innovative portfolio and pipeline.”OVERALL FINANCIAL ...
Source: Johnson and Johnson - October 18, 2022 Category: Pharmaceuticals Tags: Financial Source Type: news
[Ad hoc announcement pursuant to Art. 53 LR] Roche records solid results for the first nine months of 2022
Group salesup 2%[1] at constant exchange rates (CER) and 1% in Swiss francs; as expected, significantly lower COVID-19-related sales in both divisions in the third quarterSales in the Pharmaceuticals Divisionat the previous year ’s level with significantly lower sales of COVID-19-related products (Ronapreve and Actemra/RoActemra) and losses to biosimilars, offset by strong growth of newer medicinesSales in the Diagnostics Divisionrise 6%; base business remains strong; as expected, demand for COVID-19 tests sharply down in third quarterHighlights in the third quarter:EU approval forVabysmo (severe eye diseases)US approval...
Source: Roche Investor Update - October 18, 2022 Category: Pharmaceuticals Source Type: news
[Ad hoc announcement pursuant to Art. 53 LR] Roche records solid results for the first nine months of 2022
Basel, 18 October 2022Group salesup 2%1 at constant exchange rates (CER) and 1% in Swiss francs; as expected, significantly lower COVID-19-related sales in both divisions in the third quarterSales in the Pharmaceuticals Divisionat the previous year ’s level with significantly lower sales of COVID-19-related products (Ronapreve and Actemra/RoActemra) and losses to biosimilars, offset by strong growth of newer medicinesSales in the Diagnostics Divisionrise 6%; base business remains strong; as expected, demand for COVID-19 tests sharply down in third quarterHighlights in the third quarter:EU approval forVabysmo (severe eye ...
Source: Roche Media News - October 18, 2022 Category: Pharmaceuticals Source Type: news
Results of Novel Clinical Study of Guselkumab and Golimumab Combination Therapy Show Adults with Moderately to Severely Active Ulcerative Colitis Maintained Higher Rates of Clinical, Histologic, and Endoscopic Remission at Week 38
SPRING HOUSE, PENNSYLVANIA, October 10, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced data from an ongoing analysis of a Phase 2a clinical trial showing adults with moderately to severely active ulcerative colitis (UC) who received 12 weeks of combination induction therapy with guselkumab and golimumab, followed by a transition to guselkumab alone for maintenance, achieved a clinical remission ratea (based on the modified Mayo score [mMayo])b at week 38 of 47.9 percent, a higher rate than induction and maintenance treatment with either guselkumab alone (31.0 percent) or golimumab al...
Source: Johnson and Johnson - October 10, 2022 Category: Pharmaceuticals Source Type: news
NIDCR Requests Input on Proposed Research Initiatives
NIDCR Home | Careers | Contact
Announcements
The National Institute of Dental and Craniofacial Research (NIDCR) requests your input on six proposed concepts (research initiatives) presented at the September 2022 National Advisory Dental and Craniofacial Research Council meeting. The six initiatives are listed below. To read the full initiative descriptions and provide input, please visit: NIDCR Requests Input on FY 2023 Proposed Research Initiatives
Initiatives:
...
Source: NIDCR Science News - October 6, 2022 Category: Dentistry Source Type: news
TePe supports the Pink Ribbon initiative in favour of cancer awareness and research
This October, oral health company TePe will once again support the Pink Ribbon by offering health-promoting products in favour of cancer research. October is the breast cancer awareness month when organisations and individuals join forces to support cancer research. As an international company committed to sustainability and health awareness, TePe engages in Pink Ribbon initiatives all over the world. Last year, TePe ’s global initiatives contributed over €100,000 to the cause. Katia Saltidou, Marketing Director at TePe, said, “We constantly work to promote long-term health and encourage conscious choices, so natural...
Source: Dental Technology Blog - October 3, 2022 Category: Dentistry Source Type: news
U.S. Court of Appeals Hears Challenge to J & J ’s Bankruptcy Plan
Johnson & Johnson’s controversial bankruptcy filing, designed to limit its soaring talc liabilities, was challenged Sept. 26 before the United States Court of Appeals for the Third Circuit in Philadelphia.
A three-judge panel heard oral arguments on whether Johnson & Johnson should be permitted to shift billions of dollars in mass tort liabilities to a newly created entity, which immediately filed for bankruptcy.
The court’s decision is not expected until later in 2022. Regardless of the outcome, several legal experts believe yet another appeal will be filed with the U.S. Supreme Court.
Attorneys repre...
Source: Asbestos and Mesothelioma News - September 28, 2022 Category: Environmental Health Authors: Fran Mannino Source Type: news
FDA Panel Gives Thumbs Down to Oral Drug for NSCLC With Rare HER2 Mutations
(MedPage Today) -- An FDA advisory committee decided that the clinical benefits of the multitargeted tyrosine kinase inhibitor (TKI) poziotinib do not outweigh its risks for patients with non-small cell lung cancer (NSCLC) harboring HER2 exon 20... (Source: MedPage Today Public Health)
Source: MedPage Today Public Health - September 22, 2022 Category: American Health Source Type: news
Neoadjuvant Pembrolizumab Not Tied to More AEs in Oral Cavity SCC
No increased perioperative morbidity seen among patients with local regionally advanced oral cavity squamous cell carcinoma (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - September 15, 2022 Category: Cancer & Oncology Tags: Oncology, ENT, Pharmacy, Surgery, Journal, Source Type: news
Neoadjuvant Pembrolizumab Not Tied to More AEs in Oral Cavity SCC
THURSDAY, Sept. 15, 2022 -- Among patients with local regionally advanced oral cavity squamous cell carcinoma, rates of postoperative adverse events appear to be similar for those receiving neoadjuvant pembrolizumab or standard-of-care treatment,... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - September 15, 2022 Category: Pharmaceuticals Source Type: news
Sign in your mouth that could indicate ‘something serious’ like cancer - if it won't heal
Mouth ulcers can develop for many reasons and usually heal on their own accord, however, if they continue to give you trouble it could be a warning that something more serious is happening. (Source: Daily Express - Health)
Source: Daily Express - Health - September 13, 2022 Category: Consumer Health News Source Type: news
Could Nivolumab Prevent Oral Cancer in High-Risk Patients? Could Nivolumab Prevent Oral Cancer in High-Risk Patients?
Giving the immunotherapy nivolumab to patients with oral proliferative leukoplakia not only reduces lesions but also may prevent cancer progression, suggests the first study in the preventive setting.Medscape Medical News (Source: Medscape Allergy Headlines)
Source: Medscape Allergy Headlines - September 13, 2022 Category: Allergy & Immunology Tags: Hematology-Oncology News Source Type: news
At-Home Test for Oral/Throat Cancer Launched in US At-Home Test for Oral/Throat Cancer Launched in US
The test is marketed directly to the general public. An expert says it has ' potential ' but is concerned about false negative and positive results.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - August 29, 2022 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
Final Analysis of Phase 2 GRIFFIN Study Presented for DARZALEX ® (daratumumab)-based Investigational Quadruplet Regimen in Patients with Newly Diagnosed, Transplant-Eligible Multiple Myeloma
LOS ANGELES, August 27, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today the final results from the randomized Phase 2 GRIFFIN study evaluating the investigational use of DARZALEX® (daratumumab) in combination with lenalidomide (Revlimid®), bortezomib (VELCADE®) and dexamethasone (DARZALEX®-RVd), followed by maintenance therapy with DARZALEX®-lenalidomide (R), compared to RVd followed by maintenance therapy with R alone, in patients with newly diagnosed, transplant-eligible multiple myeloma. Data were presented in the plenary session at the 19th International Myeloma Society (IMS)...
Source: Johnson and Johnson - August 28, 2022 Category: Pharmaceuticals Source Type: news
